Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MucoShield is a preclinical-stage intranasal vaccine developed by Prime Vector Technologies for the prevention of Human Metapneumovirus (HMPV) infection. It utilizes a multivalent antigen design delivered via an Orf virus (ORFV) viral vector platform. The vaccine is specifically designed to activate mucosal immunity at the site of entry, providing a localized defense against HMPV, which is a significant cause of upper and lower respiratory tract infections in children, the elderly, and immunocompromised individuals. By utilizing the ORFV vector, MucoShield aims to induce both robust mucosal and systemic immune responses without the need for traditional adjuvants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MucoShield.